Anthem Biosciences Q1 FY27: Revenue, Profit Fall

What Anthem Biosciences reported for Q1 FY27

Anthem Biosciences Limited announced its consolidated financial results for the quarter ended 30 June 2026 (Q1 FY27). The update showed a softer quarter on key metrics compared with both the preceding quarter and the year-ago period. The company reported consolidated net profit of ₹119.94 crore for the quarter. Revenue from operations (consolidated) was reported at ₹418.22 crore.

A separate snapshot in the provided data also flagged near-term pressure, noting standalone revenue of about ₹384 crore and standalone net profit of about ₹102 crore for the quarter. Taken together, the disclosures point to a quarter where profitability and growth moderated, even as the core CRDMO business continued to drive most of the revenue.

Revenue movement: sequential decline and YoY drop

The company’s revenue from operations for the June 2026 quarter was ₹418.22 crore. This was lower than ₹610.94 crore in the preceding quarter ended 31 March 2026. It was also below ₹540.21 crore in the year-ago quarter ended 30 June 2025.

In percentage terms, the company stated revenue from operations declined 31.54% quarter-on-quarter and 22.58% year-on-year. Separately, the “Data Snapshot” section in the provided text highlighted a comparison of ₹384 crore versus ₹538 crore, describing an about 28.62% YoY decline. The same text later provides standalone revenue at ₹383.84 crore, which aligns closely with the ₹384 crore figure.

Profitability: consolidated profit, and standalone profit pressure

Anthem Biosciences reported consolidated net profit of ₹119.94 crore for Q1 FY27. Profit before tax (PBT) for the quarter was ₹144.58 crore. The PBT was lower than ₹277.92 crore in the preceding quarter and ₹186.25 crore in the year-ago quarter, based on the figures shared.

On a standalone basis, profit for the quarter was reported at ₹102.01 crore. The “Data Snapshot” also compared standalone net profit of ₹102 crore versus ₹148 crore in the corresponding quarter of the previous fiscal year, translating to an approximate 31.08% YoY decline.

Expenses and cost line items investors tracked

Total expenses for the quarter stood at ₹298.53 crore. This was lower than ₹385.22 crore in the preceding quarter and ₹376.77 crore in the year-ago quarter, as per the company’s reported numbers.

One cost line item moved in the opposite direction. Employee benefit expenses were ₹78.84 crore for the quarter, higher than ₹72.48 crore in the preceding quarter and ₹72.03 crore in the year-ago quarter. These movements help explain how margins can remain under watch even when total expenses decline.

Segment mix: CRDMO remained the revenue backbone

The company disclosed revenue contributions for two segments. The CRDMO segment contributed ₹340.80 crore to total revenue for the quarter. Speciality Ingredients generated ₹77.42 crore in revenue.

The segment split indicates that the CRDMO business continued to account for the bulk of quarterly revenue. The Telugu-language section of the provided text also described CRDMO as playing a key role in revenue during the quarter, consistent with the segment numbers.

Corporate actions and governance updates during the quarter

Anthem Biosciences reported that its paid-up equity share capital as of 30 June 2026 was ₹112.68 crore. During the quarter, the company allotted 1,670,909 fully paid-up equity shares under its ESOP Scheme 2024.

The results were reviewed by the audit committee and approved by the board on 21 July 2026, according to the provided text. The same material also referenced that a board meeting was scheduled on 21 July 2026 to consider the unaudited standalone and consolidated financial results for Q1 FY27.

Key numbers table: Q1 FY27 versus recent reference points

Market snapshot and what changed versus last year

The “Market snapshot” section described a double-digit decline in consolidated top-line and standalone bottom-line versus the same period last year. It also listed consolidated Q1 revenue at ₹384 crore versus ₹538 crore, while the detailed results section lists consolidated revenue from operations at ₹418.22 crore and the Telugu portion lists standalone revenue at ₹383.84 crore. Investors typically reconcile such differences by checking definitions used across sources (consolidated vs standalone, and “revenue” vs “revenue from operations”).

Still, the direction of travel was consistent across the disclosures: revenue and profit were lower year-on-year, and sequential revenue was sharply lower compared with the March 2026 quarter.

Broader context: how the quarter sits against FY26 and Q4 trends

The provided material includes FY26 and Q4 FY26 reference data that highlights how strong the immediately preceding quarter was. Q4 FY26 consolidated revenue was reported at ₹610.94 crore, and net profit at ₹189.76 crore. FY26 revenue was reported at ₹2,124.33 crore.

The same dataset also noted a net cash position of ₹1,374.30 crore for the latest quarter in that snapshot. It also listed market cap at ₹42,284.69 crore and CMP at ₹750.8, offering additional context on how the market was valuing the business around the results period.

Analysis: why Q1 FY27 mattered for investors

For Anthem Biosciences, Q1 FY27 reinforced the importance of monitoring both the quarterly revenue trajectory and cost structure. Consolidated revenue from operations fell meaningfully versus Q4 FY26, and profitability metrics in the results note also moved lower. At the same time, total expenses declined sequentially and year-on-year, while employee costs rose, highlighting a mixed cost picture.

Segment data showed CRDMO contributing ₹340.80 crore, keeping it central to the company’s operating performance. The company’s ESOP allotment and the reported paid-up equity capital are also relevant for shareholders tracking dilution and capital structure changes.

Conclusion

Anthem Biosciences’ Q1 FY27 results showed a weaker quarter, with consolidated revenue from operations at ₹418.22 crore and consolidated net profit at ₹119.94 crore, while standalone profit was reported at ₹102.01 crore. CRDMO remained the largest revenue contributor at ₹340.80 crore, with Speciality Ingredients at ₹77.42 crore. The board approved the results on 21 July 2026, and investors will likely track subsequent quarters for signs of stabilisation after the sharp sequential decline from Q4 FY26.